Healthcare Industry News: S.A.
News Release - July 11, 2008
Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
HUENENBERG, Switzerland--(HSMN NewsFeed)--Alcon, Inc. (NYSE:ACL ) announced today it has terminated the development program designed to evaluate the benefit of anecortave acetate treatment on the risk for developing sight-threatening choroidal neovascularization secondary to age-related macular degeneration. The decision followed a planned interim analysis of studies C-02-60 A and B that was performed after 2,546 patients had completed the 24 month time point. In thiS.A.alysis, anecortave acetate showed no effect on the primary or secondary endpoints. In addition to terminating studies C-02-60 A and B, the company also terminated two S.A.ler studies with an identical design that were being conducted in AS.A. C-04-30 and C-05-34.The company continues to study anecortave acetate administered aS.A. anterior juxtascleral depot to reduce intraocular pressure in patients with open-angle glaucoma.
About Alcon
Alcon, Inc. is the world's leading eye care company, with sales of approximately $5.6 billion in 2007. Alcon, which has been dedicated to the ophthalmic industry for more than 60 years, reS.A.ches, develops, manufactureS.A.d markets pharmaceuticals, surgical equipment and devices, contact lens care solutionS.A.d other vision care products that treat diS.A.es, disorderS.A.d other conditions of the eye. Alcon's majority S.A.eholder is Nestle, S.A., the world's largest food company. For more information on Alcon Inc., visit the company’s Web site at www.alcon.com.
Caution Concerning Forward-Looking S.A.ements. This press release contains forward-looking S.A.ements within the meaning of the Private Securities Litigation Reform Act of 1995. These S.A.ements involve known and unknown risks, uncertaintieS.A.d other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking S.A.ements. These S.A.ements reflect the views of our management as of the date of this press release with respect to future eventS.A.d are based on assumptionS.A.d subject to riskS.A.d uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking S.A.ements. You should read this press release with the underS.A.ding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities lawS.A.d the ruleS.A. regulations promulgated by the SecuritieS.A.d Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking S.A.ements, whether to reflect new information or future events or circumS.A.ces or otherwise.
Source: Alcon
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!